- Home
- OCS vs DNA Comparison
OCS vs DNA Comparison
Compare OCS & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCS
- DNA
- Stock Information
- Founded
- OCS 2003
- DNA 2008
- Country
- OCS Switzerland
- DNA United States
- Employees
- OCS N/A
- DNA N/A
- Industry
- OCS Biotechnology: Pharmaceutical Preparations
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCS Health Care
- DNA Health Care
- Exchange
- OCS Nasdaq
- DNA Nasdaq
- Market Cap
- OCS 869.8M
- DNA 895.1M
- IPO Year
- OCS N/A
- DNA N/A
- Fundamental
- Price
- OCS $21.71
- DNA $13.64
- Analyst Decision
- OCS Strong Buy
- DNA Strong Sell
- Analyst Count
- OCS 4
- DNA 1
- Target Price
- OCS $41.00
- DNA $9.00
- AVG Volume (30 Days)
- OCS 77.9K
- DNA 1.8M
- Earning Date
- OCS 11-06-2025
- DNA 11-11-2025
- Dividend Yield
- OCS N/A
- DNA N/A
- EPS Growth
- OCS N/A
- DNA N/A
- EPS
- OCS N/A
- DNA N/A
- Revenue
- OCS $960,668.00
- DNA $230,815,000.00
- Revenue This Year
- OCS $36.75
- DNA N/A
- Revenue Next Year
- OCS $1,261.53
- DNA $14.41
- P/E Ratio
- OCS N/A
- DNA N/A
- Revenue Growth
- OCS N/A
- DNA 25.21
- 52 Week Low
- OCS $14.00
- DNA $5.00
- 52 Week High
- OCS $23.08
- DNA $17.58
- Technical
- Relative Strength Index (RSI)
- OCS 76.98
- DNA 49.81
- Support Level
- OCS $21.19
- DNA $13.16
- Resistance Level
- OCS $21.79
- DNA $16.50
- Average True Range (ATR)
- OCS 0.66
- DNA 1.53
- MACD
- OCS 0.28
- DNA -0.16
- Stochastic Oscillator
- OCS 93.88
- DNA 23.35
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.